Two directors, Daniel Geffken and Leslie J. Williams, resigned from Windtree Therapeutics' Board on August 13, 2024, and were replaced by Jed Latkin and Saundra Pelletier, who were appointed as new directors on the same day. Additionally, Mark Strobeck, Ph.D., was appointed as the lead independent director.